Regeneron announced phase 3 development of a combination of Eylea and the angiopoietin2 antibody nesvacumab is not warranted after two phase 2 trials failed to show sufficient differentiation, according to a company press release.
The RUBY study, which evaluated patients with diabetic macular edema, and the ONYX study, which evaluated patients with wet age-related macular degeneration, were both randomized, double-masked, active-controlled phase 2 studies that investigated if the combination of Eylea (aflibercept) and nesvacumab would have a benefit over Eylea alone. The combination did not
Uncategorized